CLINICAL TRIALS PROFILE FOR CAMPTOSAR
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Camptosar
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT00177853 ↗ | Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer | Terminated | Pharmacia and Upjohn | Phase 1 | 2006-12-01 | The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision. |
| New Combination | NCT00177853 ↗ | Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer | Terminated | University of Pittsburgh | Phase 1 | 2006-12-01 | The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision. |
| New Combination | NCT00215982 ↗ | Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer | Completed | Roche Pharma AG | Phase 2 | 2004-12-01 | The purpose of this study is to find out how effective the new combination of the drugs Capecitabine (Xeloda), Oxaliplatin (Eloxatin), and Irinotecan (Camptosar) are against colon and rectal cancer. All three of these drugs are approved by the Food and Drug Administration (FDA) for the treatment of colon or rectal cancer. This however is the first time that these three drugs have been combined in this schedule for the treatment of colon/rectal cancer. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Camptosar
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003970 ↗ | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | Completed | National Cancer Institute (NCI) | Phase 1 | 1999-01-01 | Phase I trial to study genetic testing and the effectiveness of irinotecan in treating patients who have solid tumors and lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Genetic testing for a specific enzyme may help doctors determine whether side effects from or response to chemotherapy are related to a person's genetic makeup |
| NCT00004078 ↗ | Irinotecan in Treating Children With Refractory Solid Tumors | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-10-01 | This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
| NCT00004078 ↗ | Irinotecan in Treating Children With Refractory Solid Tumors | Completed | Children's Oncology Group | Phase 2 | 1999-10-01 | This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Camptosar
Condition Name
Clinical Trial Locations for Camptosar
Trials by Country
Clinical Trial Progress for Camptosar
Clinical Trial Phase
Clinical Trial Sponsors for Camptosar
Sponsor Name
